PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.\', \'Fosun Pharma, Boston, MA, USA. aimin.hui@fosunpharma.com.\', \'Taizhou City Center for Disease Control and Prevention, Taizhou, China.\', \'Fosun Pharma, Beijing, China.\', \'Taizhou Vaccine Clinical Research Center, Taizhou, China.\', \'Department of Pharmacy, Army Medical University, Chongqing, China.\', \'Fosun Pharma, Boston, MA, USA.\', \'Taizhou People\'s Hospital, Taizhou, China.\', \'BioNTech SE, Mainz, Germany.\', \'Taizhou People\'s Hospital, Taizhou, China. tzheart@126.com.\', \'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. jszfc@vip.sina.com.\', \'Center for Global Health, Nanjing Medical University, Nanjing, China. jszfc@vip.sina.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41591-021-01330-9
?:hasPublicationType
?:journal
  • Nature medicine
is ?:pmid of
?:pmid
?:pmid
  • 33888900
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.067
?:rankingScore_hIndex
  • 484
?:title
  • Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33888900>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33888900>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all